Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome

Plain-language summary

This observational study examines mesenchymal stem cells and the contribution of the tumor microenvironment to outcomes in NPM1-mutated low-risk acute myeloid leukemia. Adult patients with newly diagnosed acute myeloid leukemia could take part. It was a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Start date

3/15/2023

Estimated completion

3/15/2025

Countries

Italy

Related genes

Locations

• Pavia, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Adult patients with new onset Acute Myeloid Leukemia diagnosed.

Exclusion Criteria:

\-